NASDAQ
16.01.25
21:41 Uhr
1,070 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.01. | NeuroOne Announces Preliminary Q1 Fiscal 2025 Revenue Of $6.2 Mln | 2 | RTTNews | ||
| 10.01. | NeuroOne Medical Technologies announces higher Q1 prelim revenue | 2 | Seeking Alpha | ||
| 10.01. | NeuroOne Medical Technologies Corporation: NeuroOne Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million | 79 | GlobeNewswire (Europe) | First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar... ► Artikel lesen | |
| 10.01. | NEUROONE MEDICAL TECHNOLOGIES Corp - 8-K, Current Report | - | SEC Filings | ||
| 06.01. | NeuroOne Medical Technologies Corp: NeuroOne Announces Change of Virtual Investor Webinar to Friday, January 10, 2024 | 1 | GlobeNewswire (USA) | ||
| 03.01. | NeuroOne Medical Technologies Corp: NeuroOne Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST | 1 | GlobeNewswire (USA) | ||
| NEUROONE MEDICAL TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 19.12.24 | NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 17.12.24 | NeuroOne Medical Technologies GAAP EPS of -$0.46, revenue of $3.45M | 4 | Seeking Alpha | ||
| 17.12.24 | NeuroOne reports 77% increase in product revenue in 2024 | 1 | Seeking Alpha | ||
| 17.12.24 | NeuroOne Medical Technologies Corp: NeuroOne Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025 | 111 | GlobeNewswire (Europe) | Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 (GLOBE... ► Artikel lesen | |
| 17.12.24 | NEUROONE MEDICAL TECHNOLOGIES Corp - 8-K, Current Report | - | SEC Filings | ||
| 17.12.24 | NEUROONE MEDICAL TECHNOLOGIES Corp - 10-K, Annual Report | - | SEC Filings | ||
| 05.12.24 | NeuroOne-Aktie erreicht 52-Wochen-Tief bei 0,56 US-Dollar | 1 | Investing.com Deutsch | ||
| 05.12.24 | Neuroone stock hits 52-week low at $0.56 amid market challenges | 1 | Investing.com | ||
| 04.12.24 | NeuroOne Medical Technologies Corp: NeuroOne to Report Fourth Quarter and Fiscal Year 2024 Financial Results on December 17 at 9:00 a.m. Eastern Time | 1 | GlobeNewswire (USA) | ||
| 27.11.24 | Neuroone stock hits 52-week low at $0.59 amid market challenges | 1 | Investing.com | ||
| 27.11.24 | Neuroone-Aktie erreicht 52-Wochen-Tief bei 0,59 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.11.24 | NeuroOne Medical Technologies Corporation to Present at November 21st Virtual Investor Summit Microcap Event | 218 | ACCESS Newswire | EDEN PRAIRIE, MN / ACCESSWIRE / November 13, 2024 / NeuroOne Medical Technologies Corporation (Nasdaq:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical... ► Artikel lesen | |
| 08.11.24 | NeuroOne ends loan agreement with Growth Opportunity Funding | 1 | Investing.com | ||
| 08.11.24 | NEUROONE MEDICAL TECHNOLOGIES Corp - 8-K, Current Report | - | SEC Filings |
Seite:
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 36,330 | +2,05 % | Formycon und Fresenius Kabi: Zulassung für Otulfi in Großbritannien | Die Formycon AG und Fresenius Kabi haben die Zulassung von FYB202/Otulfi durch die britische Arzneimittelbehörde MHRA bekannt gegeben. Das Biosimilar zu Stelara ist für die Behandlung schwerer entzündlicher... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 78,76 | +0,57 % | Spruce Point Sees Trouble Ahead For Procept BioRobotics | ||
| GENEDX | 68,47 | 0,00 % | GeneDx Announces Preliminary 2024 Financial Results | STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for... ► Artikel lesen | |
| BIOMERICA | 0,702 | 0,00 % | Biomerica, Inc.: Biomerica Reports Second Quarter Fiscal 2025 Financial Results | - Total Revenue Increases 5% Year-Over-Year - Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 14,530 | 0,00 % | Alignment Healthcare sues CMS over star ratings, disapproves of federal contractor's role | ||
| ATRICURE | 37,630 | +1,79 % | AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day | MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and... ► Artikel lesen | |
| PROGYNY | 20,630 | 0,00 % | Progyny beruft Gesundheitsexpertin Debra Morris in den Vorstand | ||
| SIEMENS HEALTHINEERS | 51,28 | +0,55 % | AKTIEN IM FOKUS: Siemens Healthineers legt zu - EU bestätigt unfaire China-Bedingungen | FRANKFURT (dpa-AFX Broker) - Die Aktien von Siemens Healthineers haben am Dienstagmittag zugelegt. Die Papiere der Forchheimer gewannen mehr als 2 Prozent, blieben damit allerdings in der jüngsten... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 47,200 | +2,16 % | Carl Zeiss Meditec: Analyst bleibt extrem bullish! | Carl Zeiss Meditec-Aktien ISIN: DE0005313704 haben am Freitag einen guten Tag erwischt und konnten einen Teil der Verluste vom Mittwoch und Donnerstag wieder aufholen. Der Schlusskurs lag bei 46,96... ► Artikel lesen | |
| MIMEDX | 9,080 | 0,00 % | MIMEDX GROUP, INC. - 8-K, Current Report | ||
| FRESENIUS MEDICAL CARE | 44,920 | +0,22 % | Fresenius Medical Care Aktie: Positiver Start in das neue Jahr! | Die Fresenius Medical Care-Aktie verzeichnete heute einen erfreulichen Handelsverlauf an der XETRA-Börse. Der Anteilsschein stieg um 0,7 Prozent auf 43,88 EUR und markierte zwischenzeitlich ein Tageshoch... ► Artikel lesen | |
| NANO-X IMAGING | 8,345 | 0,00 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| AGILON HEALTH | 2,960 | 0,00 % | Here's Why Analysts Just Upgraded Agilon Health (AGL) | ||
| RXSIGHT | 31,140 | 0,00 % | RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance | ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,860 | +1,11 % | Privia Health Group, Inc. - 8-K, Current Report |
Das Unternehmen NEUROONE MEDICAL TECHNOLOGIES CORPORATION kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,070 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROONE MEDICAL TECHNOLOGIES CORPORATION finden Sie auf Wallstreet Online.
